Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort ...

A retrospective cohort analysis shows that pediatric patients with noninfectious uveitis face lower recurrence rates when ...

An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

Celltrion, Inc. announced that the U.S. Food and Drug Administration granted an interchangeable designation to ...

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic ...

Read the Medication Guide and Instructions for Use provided by your pharmacist before you start using adalimumab and each time you get a refill. Ask your health care professional how to prepare ...

Adalimumab had superior efficacy and safety outcomes compared with secukinumab and bimekizumab for the treatment of hidradenitis suppurativa.

Yuflyma is a high-concentration and citrate-free formulation of Humira biosimilar, approved for multiple inflammatory ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

FutureWise Research, a leading provider of market intelligence and consulting services in the healthcare industry, is pleased to announce the release of its latest in-depth market analysis report, ...